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Abstract
Background and Aims: Despite the high prevalence of chronic hepatitis B (CHB) in Africa, few studies have been performed
among African patients. We sought to evaluate liver stiffness measurement by FibroScanH (LSM) and two biochemical
scores (FibroTestH, FibrometerH) to diagnose liver fibrosis in Senegalese CHB patients with HBV plasma DNA load $3.2 log10
IU/mL and normal alanine aminotransferase (ALT) values.
Methods: LSM and liver fibrosis biochemical markers were performed on 225 consecutive HBV infected Senegalese patients
with high viral load. Patients with an LSM range between 7 and 13 kPa underwent liver biopsy (LB). Two experienced liver
pathologists performed histological grading using Metavir and Ishak scoring.
Results: 225 patients were evaluated (84% male) and LB was performed in 69 patients, showing F2 and F3 fibrosis in 17%
and 10% respectively. In these patients with a 7–13 kPa range of LSM, accuracy for diagnosis of significant fibrosis according
to LB was unsatisfactory for all non-invasive markers with AUROCs below 0.70. For patients with LSM values below 7 kPa,
FibroTestH (FT), and FibrometerH (FM) using the cut-offs recommended by the test promoters suggested a fibrosis in 18% of
cases for FT (8% severe fibrosis) and 8% for FM. For patients with LSM values greater than 13 kPa, FT, FM suggested a
possible fibrosis in 73% and 70%, respectively.
Conclusion: In highly replicative HBV-infected African patients with normal ALT and LSM value below 13 kPa, FibroScanH,
FibroTestH or FibrometerH were unsuitable to predict the histological liver status of fibrosis.
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Introduction
More than 350 million patients worldwide infected with
hepatitis B virus (HBV) are living with chronic hepatitis B
(CHB) [1]. Senegal ranks among the countries with the highest
prevalence in the world; 17% of blood donors test positive in
plasma for hepatitis B virus surface antigen (HBsAg). Primarily
infected during early childhood, this population shows a high rate
of precore mutation, around 90% (HBeAg-negative) [2]. Without
treatment, 15 to 40% of subjects with chronic HBV infection will
develop cirrhosis and face a risk of developing hepato-cellular
carcinoma [3]. European updated guidelines for chronic hepatitis
B recommended assessing liver fibrosis in patients with HBV
plasma DNA load above 2,000 IU/mL or elevated ALT [4].
American guidelines differ concerning HBeAg status; they
recommend liver biopsy (LB) for HBeAg-negative patients with
persistent HBV DNA above 2,000 IU/mL and ALT level #2
ULN [5].
Treatment is recommended when LB shows moderate/severe
necroinflammation or significant fibrosis by METAVIR scoring
[4–5]. Nevertheless, LB is an invasive procedure and has rare but
potentially life-threatening complications [6–7]. Also, despite
being considered the ‘‘gold standard’’ there can be marked inter-
and intra-observer variability leading to incorrect staging in up to
33% of biopsies [8–10]. Moreover, it is difficult to perform in
developing countries because of its cost and the limited number of
histopathologists.
In resource-poor contexts, surrogate markers that enable the
non invasive measurement of fibrosis in CHB patients and serve as
an alternative to liver biopsy are badly needed. These markers
include a physical device that measures liver stiffness by
elastometry (FibroScanH) and biochemical scores developed in
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APRI, Hepascore and Fib-4 have been evaluated in Caucasian
populations with chronic hepatitis C (CHC) and, show good
correlation with liver fibrosis stage [11–17]. Strategies combining
biochemical fibrosis scores or one biochemical score with liver
stiffness measurement (LSM) by FibroScanH have decreased the
need for LB in patients with viral hepatitis; [18–20] such strategies
currently have already been widely implemented for hepatitis C
patients, particularly in France [21].
The picture is not so clear with CHB [21–27]. Whilst studies
have shown a correlation between hepatitis B virus (HBV) viral
load and liver fibrosis in HBeAg negative patients [28] there is less
evidence of a correlation between biochemical scores and liver
stiffness measurement for CHB, particularly in countries with high
CHB prevalence, with only one study involving CHB African
patients [29]. We conducted a study of HBV-infected Senegalese
patients with normal ALT values but elevated HBV DNA loads
with the following objectives:
1- To compare the results of LSM and biochemical
scores (FibroTestH, FibrometerH).
2- To compare liver biopsy with LSM and biochemical
scores (FibroTestH, FibrometerH) for predicting liver
fibrosis in patients with LSM between 7 and 13 kPa.
Materials and Methods
Patients were consecutively enrolled by private practitioners and
by four public hospitals in Dakar, Senegal’s capital city, from
December 2006 to June 2008. Treatment-naı ¨ve patients above 18
years old, with positive HBsAg over six months, symptom-free,
HIV, HCV and HDV negative, and with a serum HBV DNA
level $3.2 log10 IU/mL were eligible for enrolment. All study
participants underwent LSM, FT and FM on the same day. The
study’s scientific committee limited the LB to patients with LSM
values ranging between 7 kPa and 13 kPa. This decision was
based on published studies of CHC patients, in which patients with
LSM#7 kPa were assumed to have #F1 METAVIR stage.
Conversely, people with LSM$13 kPa were assumed to have F4
METAVIR stage, and thus no indication of LB [30].
The protocol was in accordance with Declaration of Helsinki
ethical guidelines and was approved by the Senegalese ethics
committee. Patients fulfilling the inclusion criteria were enrolled
after providing written and informed consent. Patients eligible for
treatment were prescribed Lamivudine free of charge and included
in a national hepatitis B program.
Liver stiffness measurements (LSM) of FibroScanH
LSM was performed in the right lobe of the liver through the
intercostal spaces, with the patient lying in the dorsal decubitus
position, right arm in maximal abduction. After receiving expert
training, four physicians performed LSM. Several successful
acquisitions were performed on each patient. The result was
expressed as the median value of 10 successful acquisitions. The
inter-quartile range (IQR) was also assessed.
Liver histology and fibrosis quantification
LB was performed within six months of non-invasive markers
evaluation.
Liver biopsies were obtained using 16G disposable needles
(Hepafix; B. Braun, Melsungen, Germany). Fibrosis staging was
considered reliable when the liver specimen length was $15 mm
or the portal tract number $10 [31].
Liver specimens were stained with hematoxylin-phloxin-saffran
and picrosirius red and interpreted by two highly experienced liver
pathologists (MC, JLS), who were unaware of LSM, clinical, and
biological data.
Liver fibrosis was scored on a 0–4 scale according to the
METAVIR scoring system [32]. Necroinflammatory activity,
based on assessment of interface activity and lobular necrosis,
was graded on a 4-point scale [32].
Serum markers of fibrosis
Two non invasive serum methods were assessed: FibroTestH
[12], and FibrometerH [13]. The following parameters were
determined on blood sampled the same day as LSM onto a Vitros
automat (Ortho Clinical Diagnostics, Issy-les-Moulineaux,
France): aspartate aminotransferase (AST), alanine aminotrans-
ferase (ALT), c-glutamyl transpeptidase, total bilirubin, platelet
count, HBe antigen, urea and prothrombin time.
Alpha2-macroglobulin, apolipoprotein A1, haptoglobin, hya-
luronic acid and hepatitis B viral load were performed in a
specialized laboratory (Biomnis, Lyon, France). Scores for the
FibroTestH (FT) were calculated by Biopredictive (Paris, France).
Biolivescale (Pr Cale `s, Angers, France) generously provided scores
for the FibrometerH (FM). All patients in whom haemolysis could
influence the biochemical scores were excluded from the analysis.
Both FT and FM markers were evaluated blindly to the results
of LSM and LB. Results were evaluated in both quantitative and
METAVIR scores from F0 to F4.
Virological analyses
The HBV DNA quantification was assayed using the Cobas
AmpliPrep/Cobas Taqman HBV test, v1.0 assay (Roche Diag-
nostics, Meylan, France), with a detection threshold of 12 IU/mL
(1.1 log10 IU/mL).
Statistical analysis
Quantitative variables were expressed as mean6standard-
deviation (SD) or median and interquartile range [IQ1–IQ3]
and discrete variables by percentages. Differences among
percentages were analyzed using the Fisher’s exact test.
LSM was categorized in three classes: ,7 kPa, between 7 and
13 kPa, and $13 kPa. The number of patients with an
IQR.33% of the results of the examination was given.
Agreement between the two pathologists for METAVIR of liver
specimens was evaluated using the Kappa coefficient with the
interpretation scale of Landis-Koch [33].
A comparison of METAVIR staging from LB to LSM and
biochemical markers was conducted only on patients with LSM
values between 7 and 13 kPa.
With LB as the gold standard, the diagnostic performance of
each non-invasive marker was evaluated by performing the Area
under the ROC curve (AUROC) with 95% confidence interval
(CI). AUROCs were compared with the rocgold procedure [34].
Statistical analysis was performed using the STATA 10
software.
Results
Patients
Eight hundred seventy four consecutive patients who were
HBsAg positive for over six months were screened by seven
hepatologists in Dakar. Eighty-three patients with ALT values
above the normal were ineligible based on study criteria.
Among the 791 with normal ALT values, 277 patients had
HBV DNA level $3.2 log10 IU/mL and 226 underwent LSM.
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(Figure 1).
Patient characteristics
The population was primarily male (84%) with a mean age of
30 years. The median viral load was 3.6 log10 IU/mL, and 91% of
patients were HBeAg negative. LSM ranged from 3.3 to 39.1 kPa,
with median value of 6.6 kPa. Twenty seven patients (12%) had
IQR values greater than 33%. One hundred and thirty three
patients (59%) had values of less than 7 kPa, 80 (36%) had values
between 7 and 13 kPa, and 12 (5%) had values greater than
13 kPa (Table 1).
Fifty-one percent of the patients scored $2 (with F1–F2
considered to be F2) for the FT, while 69 percent of the patients
scored $F2 for the FM. Using this threshold of F2 to initiate
treatment, the serum markers were in concordance in 139 patients
(70%) and differed in 60 patients (30%).
The proportion of patients with values equal to F1–F2, i.e. in
the grey zone, was 26% (58/220) and 50% (102/204) for FT and
FM markers, respectively.
The proportion of patients identified as F3–F4 was 18% (40/
220: 26 F3, 2 F3–F4 and 12 F4) for FT and 2.5% (5/204) for FM
markers.
Comparison between histology and non invasive
markers
A liver biopsy was performed in 71 of the 80 patients with LSM
values between 7 and 13 kPa. The other nine patients declined to
be biopsied. For two patients, the LB result was not retained
because the LB specimens contained less than 10 portal tracts.
Therefore, comparison between LB and LSM, FT and FM could
be made in 69 patients.
For 64 patients (93%), the period between liver biopsy and non-
invasive markers evaluation was less than two months, with all
patients biopsied within a delay of less than 6 months.
The median biopsy length was 30 mm [25–34], with a median
of 24 [20–30] portal tracts.
Fifty (72%) of the 69 patients had absent/mild fibrosis
(METAVIR F0–F1), 12 (17%) had significant fibrosis (F2) and 7
(10%) had severe fibrosis (F3). There was no report of F4 stage.
In patients identified with a fibrosis stage equal to F2 at LB,
LSM ranged from 7.1 to 11 kPa. In patients with a fibrosis stage
equal to F3, LSM values ranged from 7.8 to 12 kPa.
The grades of activity were classified as A0 in 43 cases (62%),
A1 in 20 cases (29%) and A2 in six cases (9%).
Figure 1. Flow chart.
doi:10.1371/journal.pone.0022291.g001
Table 1. Main characteristics of the 225 patients with CHB.
Demographics
Sex, Male (n,%) 188 (84)
Age* (yrs) 3068
BMI* (kg/m2) 21.463.3
HBV infection
HBe antigen positive (n,%) 21 (9)
HBV viral load* (Log IU/mL) 4.061.1
$4.2 Log IU/ml (n,%) 50 (22)
Biochemical data
Platelets* (10
3/mm
3)1 9 5 653
Prothrombin time* (% of normal) 8566
,80 (n,%) 66 (29)
Total bilirubin* (mol/L) 13.466.0
cglutamyl transpeptidase* (IU/L) 31624
AST* (IU/L) 35622
ALT* (IU/L) 36610
Non Invasive Fibrosis Markers
LSM values** (kPa) 6.6 (5.4–8.7)
IQR.33% (n,%) 27 (12)
,7 (n,%) 133 (59)
[7–13[ (n,%) 80 (36)
$13 (n,%) 12 (5)
FibroTestH* 0.32 (0.21–0.49)
,F2 (n,%) 107 (49)
$F2*** (n,%) 113 (51)
FibrometerH* 0.45 (0.34–0.58)
,F2 (n,%) 64 (31)
$F2** *(n,%) 140(69)
*mean6SD,
**Median [IQ1–IQ3],
***F1–F2 considered as $F2.
doi:10.1371/journal.pone.0022291.t001
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significant fibrosis was 0.7160.11.
Figure 2 shows box-plots of LSM and the two biochemical
scores versus METAVIR fibrosis stages. There was no clear
correlation between the values of the LSM and two biological
markers and the LB METAVIR Scores.
The AUROC values for FibroScanH, FibroTestH and Fibro-
meterH were 0.61 [CI95%: 0.45–0.77], 0.55 [CI95%: 0.39–0.71],
and 0.68 [CI95%: 0.53–0.82], respectively. No differences were
observed when patients with an IQR for LSM greater than 33%
were excluded from the analysis.
Comparison of AUROCs of all non-invasive markers two by
two detected no significant difference.
When considering the 12 patients with LSM values greater than
13 as having a fibrosis stage equal or greater than F2, the
performances of the three non-invasive markers were improved,
especially for LSM with an AUROC value of 0.76 [0;64–0.88].
Comparison of FibroTestH and FibrometerH results
expressed as METAVIR scoring stages and LSM values
Table 2 reports results of FT and FM expressed as METAVIR-
like scores and LSM values.
– For patients with LSM,7 kPa, 43% of patients were classified
as F1–F2 or $F2 by FT and 57% by FM. Among the 116
patients with both FT and FM results, 39 patients (34%) were
classified as F1–F2 or with stages requiring a treatment ($F2).
No patients had Metavir stage $F3 by FM. Conversely, seven
patients, all men, displayed a Metavir score $F3 (2 patients
F3–F4 and 5 patients F4) by FT. Table 3 summarizes for these
seven patients the parameters used to calculate FT scores and
FM scores. For six out of seven subjects, haptoglobin value was
very low (,0.1 g/L). Haemolysis was not reported for these
patients. In contrast, among the 121 patients with LSM,7 kPa
and Metavir stages by FT,F3, only six (5%) had haptoglobin
value ,0.1 g/L.
– For patients with LSM values over 13 kPa, 73% and 70% of
patients had an FT and FM equivalent of $F2–F3,
respectively, with one patient having a FT measure of #F1
(F1–F2 by FM), one patient measuring F1–F2 by both serum
markers, and one patient measuring F3 by FT but F1–F2 by
FM.
– Among the 73 patients with LSM values between 7 and
13 kPa, nine (12%) were classified #F1 by the two markers,
and 40 (55%) were classified $F1–F2 for both markers
(figure 3).
Conversely for patients classified as F3–F4 for FT or FM, the
median LSM value was 8 and 10.5 kPa, respectively. For patients
with FT or FM Metavir stages #F1–F2, LSM values were less
than 13 kPa; the median LSM was less than 7 kPa. No clear
relationship was identified between LSM values and FT or FM
scores.
Discussion
In the present study conducted on 874 patients with HBV
infection, only 10% displayed an ALT value exceeding the normal
level. For most HBV-infected patients with normal ALT,
monitoring remains problematic. Liver enzymes are generally
the only markers routinely available in developing countries, and
thus patients with normal ALT go untreated.
In Senegal, 17% of the population is considered to be HBV
infected, and more than 60% of all children are infected with HBV
by five years old [35]. The high prevalence of mutant precore in
this Senegalese population could be explained by the virus’s long
evolution and selective strain bottleneck. This high prevalence of
mutant precore limits the use of HBe antigen detection as a
surrogate marker of HBV replication [2]. Since techniques of
Figure 2. Box plots of LSM, FibroTestH and FibrometerH scores according METAVIR stages from Liver Biopsy.
doi:10.1371/journal.pone.0022291.g002
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African countries, they could also be used in HBV quantification.
Patients with significant viral loads should undergo a liver
fibrosis assessment before considering antiviral treatment. In this
study among the patients with normal ALT values, 36% had a
viral load greater than 3.2 log10 IU/mL, and 22% had values
greater than 4.2 log10 IU/mL, reflecting an active infection, as LB
results confirmed. Liver biopsy, however, remains difficult to
perform in resource-poor countries, and non invasive markers are
thus crucial to identifying patients who need treatment. The
FibroScanH could be made more readily available, because the
device is easy to use and the equipment simple to maintain. In
contrast, expensive biochemical tests like FibroTestH or Fibrome-
terH are less likely to be used, since most patients cannot afford
them and local laboratories often cannot perform such specialized
tests.
Among the 69 patients with LSM between 7 and 13 kPa and an
LB, 27% had significant fibrosis and therefore should have
received treatment despite normal ALT. We found no cases at the
cirrhosis stage. The quality of the biopsy was high because of large
specimen sizes; the Kappa coefficient confirmed the consistent
agreement between the two pathologists. The accuracy of the non
invasive markers was rather low, with values of AUROC less than
0.70 for all three markers.
Various studies have already been performed using these
markers in hepatitis C infected patients, with good results in
diagnosing significant fibrosis and an AUROC of more than 0.80
in most studies [17,19,36]. Nevertheless, accuracy is always lower
in distinguishing absent/mild fibrosis (F0 or F1) from moderate
fibrosis to cirrhosis (F2, F3, F4). For CHB patients, previous
studies have been published on non-invasive markers, including
one in Africa [29]. Leroy et al. compared patients with CHB
versus those with hepatitis C for the performance of several non-
invasive markers, including FT and FM, and recorded poorer
results in CHB patients in diagnosing early stages of fibrosis [17].
Marcellin et al. showed that the performance of LSM in predicting
liver fibrosis in patients with CHB is comparable to that observed
in CHC patients. However, cut-off values differed slightly [23].
One explanation could be that nodular fibrosis in CHB patients
was less extensive than that observed in CHC patients at the same
METAVIR stage. Sebastiani et al. showed a poorer performance
of non invasive markers in CHC patients with normal transam-
inases [37].
A recent study conducted in another west African country,
Burkina Faso, reported better results for FibroTestH, FibrometerH
and FibroScanH markers to diagnose significant fibrosis with
AUROCs of approximately 0.80 for FibrometerH and FibroTestH
and 0.87 for the FibroScanH [29].
One explanation of the discrepancy between our results and
those from the Burkina study may be the larger proportion of
significant fibrosis among the Burkinabe population due to the
difference in the inclusion criteria (70% of patients presented with
a METAVIR stage at least equal to F2). The heterogeneous
recruitment of the Burkinabe study, which included patients
already receiving antiviral treatment, could account for the better
results.
Conversely, patients selected in our study represent a very
homogeneous population of chronic HBV patients, naı ¨ve to
treatment and newly referred, but the proportion of patients with
significant or severe fibrosis (12 with F2, 7 with F3, and none with
F4) do not allow any firm statistical conclusion on the correlation
between liver histology and non invasive markers.
In our study, we focused on FT and FM, as these biochemical
markers are validated and widely implemented for HCV, in
France. Low-cost, easier and simpler non-invasive methods of
assessing liver fibrosis such as APRI or Hepascore showed similar
poor performances with AUROCs at 0.62, CI95%: [0.45–0.79]
and 0.63, CI95%: [0.47–0.78] respectively (data not shown).
With regard to the three non-invasive markers performed on the
entire population of 225 patients, a large proportion of subjects
Table 2. Results of FT, FM METAVIR scoring stages according
to Liver Stiffness Measurement values.
LSM (kPa) #F1 F1–F2 F2–F3 F3–F4 Total
n( % ) n( % ) n( % ) n( % ) n
,7
FT 74 (57) 32 (25) 15 (12) 8 (6) 129
FM 52 (43) 59 (49) 9 (8) 0 (0) 120
7–13
FT 32 (40) 24 (30) 20 (25) 4 (5) 80
FM 12 (16) 40 (55) 18 (25) 3 (4) 73
$13
FT 1 (9) 2 (18) 6 (55) 2 (18) 11
FM 0 (0) 3 (30) 5 (50) 2 (20) 10
doi:10.1371/journal.pone.0022291.t002
Table 3. Values of parameters used to scoring FibroTestH and FibrometerH in the 7 patients with LSM,7 kPa and FibroTestH
METAVIR scoring stages $F3.
Age PT TB GGT Platelets HA Urea A2 M Hapto ApoA1 ALT AST LSM FT FM
19 99 22.2 27 42 25 2.82 3.81 .78 .59 39 31 4.8 F4 F2–F3
25 94 22.2 33 214 19 5.98 2.94 ,0.1 1.62 52 37 5.3 F3–F4 F1–F2
30 93 12 30 169 19 4.48 2.89 ,0.1 1.2 38 38 5.6 F3–F4 F1–F2
23 76 8.6 21 157 19 2.99 4.6 ,0.1 .90 31 35 4.6 F4 F2–F3
24 56 25.7 24 167 22 3.65 3.37 ,0.1 1.2 35 53 6.3 F4 F2–F3
26 84 12 45 237 19 1.99 3.29 ,0.1 1.11 40 30 6.1 F4 F1–F2
24 80 12 31 196 58 4.32 3.1 ,0.1 1.12 31 26 5.3 F4 F1–F2
Normal values: PT (prothrombin time):.70%, TB (total bilirubin): ,20 mmol/L, GGT,73 IU/L, Platelets:.150 Giga/L, HA (Hyaluronic acid) ,100 mg/L, Urea: 3.3–
8.3 mmol/L, A2M (Alpha-2 macroglobulin): 1.3–3 g/L, Hapto (Haptoglobin): 0.64–1.7 g/L, ApoA1 ( Apolipoprotein A1): 1.04–2.02 g/L, ALT: 72 IU/L, AST: 59 IU/L.
doi:10.1371/journal.pone.0022291.t003
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between 7 and 13 kPa for FibroScanH, 26% for FibrometerH and
up to 51% for FibroTestH.
For subjects with an LSM value of less than 7 kPa and for
whom treatment is not in theory indicated, we found 6% of
subjects for whom the FT indicated a severe fibrosis; 12% of
patients tested with the FT and 8% with FM revealed significant
fibrosis. Haptoglobin values could explain the major disparity
observed between LSM and FT. Dakar is now malaria-free, but
chronic malaria and sickle-cell anaemia which may alter liver
function were not examined in this study.
If we apply the cut-off of 7.2 kPa (close to 7) for LSM (defined in
Marcellin et al.’s recent study of 200 CHB patients as the threshold
for treatment), the rate of discordance among the three markers is
high. We reached the same conclusions when we used the optimal
cut-off of 7.3 kPa, the identical value found by Bonnard in Burkina
Faso to identify patients with significant fibrosis.
For subjects with values between 7 and 13 kPa, results were
more consistent, since all stages of fibrosis from F0 to F3 were
observed; nonetheless, discordance with LB was significant. In
contrast, all 11 subjects except two with a LSM value greater than
13 kPa had at least one of the two serum markers indicating
significant or severe fibrosis (9/11); in eight out of 11 cases (73%),
both FT and FM were concordant and thus indicated significant
or severe fibrosis.
The selection of our population for biopsy based on interme-
diate values of LSM (7–13) skewed our METAVIR fibrosis staging
on F1 and F2, the most difficult stages to differentiate.
Furthermore, liver biopsy itself has an intrinsic variability, so that
part of the misclassification of serum markers is due to failure of
liver biopsy itself to accurately differentiate between fibrosis stages.
Still another reason that these markers have performed less well,
especially when they have been used more successfully among
HCV patients in western countries and among those with more
pronounced fibrosis, may involve the nature of African HBV
infection.
Despite the high rate of HCC in Senegal, the evolution of these
patients with normal ALT is poorly understood and must be
considered for specific monitoring in which the LB remains the
cornerstone of fibrosis diagnosis.
Compared to adult HBsAg carriers in the Far East and in
Western countries, African patients have a lower rate of HBeAg
positivity. The pathogenicity of precore mutants is still incom-
pletely understood but probably generally acquired during long-
term persistent infection as escape mutants. Precore and core
mutations could be associated with more severe liver fibrosis, with
discrepancies between the histological, virological, and biochem-
ical stages. [38].
Nevertheless, considering that only two out of eleven patients
with an LSM over 13 kPa had contradictory results on
biochemical markers, LSM results over 13 kPa might be a reliable
measure for initiating treatment. Conversely, an LSM result under
7 kPa should not rule out significant fibrosis, and LB should
therefore be performed. The same rule should be applied to
patients with LSM values between 7 and 13 kPa.
As potent antivirals such as Tenofovir become more widely
available, the only current means of characterizing CHB remains
LB in patients with a viral load greater than 3.2 log/mL and
normal ALT. Further investigation of surrogate markers adapted
to local epidemiological and virological conditions are critically
needed.
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